CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 322 enrolled
Drug / intervention
Sofosbuvir 400 MG +1 moredrug
Likely dose
Sofosbuvir 400 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04885855
NCT04885855Phase 3Completed
CompareCT.gov

Efficacy and Safety of 8- Versus 12-week Sofosbuvir-ravidasvir Treatment of Non-cirrhotic Chronic Hepatitis C Patients: An Open-label, Randomized, Multicenter Study in Malaysia

Muhammad Radzi Abu Hassan·interventional·Posted May 13, 2021·Updated Mar 13, 2025

In Brief

A Phase 3 clinical trial evaluating Sofosbuvir 400 MG and Ravidasvir 200mg for Hepatitis C. Completed, enrolled 322 participants across 1 site.

Detailed Summary

This is open-label, randomized, multicentre study to compare the efficacy and safety of the 8-week versus 12-week of SOF-RVD combination treatment for non-cirrhotic chronic hepatitis C patients. All the recruited subjects will receive the treatment accordingly and be followed up for 24 weeks following the completion of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesMalaysia
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 13, 2021
Enrollment StartMar 23, 2021
Primary CompletionDec 29, 2023
Study CompletionMar 15, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.1 years ago

Interventions

Sofosbuvir 400 MGdrug

Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)

Ravidasvir 200mgdrug

Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)